Latest bloating Stories

U-M experts helped develop new evidence-based recommendations put out today by the American College of Gastroenterology U-M Health Minute: Today's top health issues and medical research ANN ARBOR, Mich., Dec. 18 /PRNewswire-USNewswire/ -- Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it's also one of the most misunderstood. That's why updated guidelines addressing the management of the condition are being released by the American...

CLEVELAND, Dec. 4 /PRNewswire/ -- Of the estimated 25 to 45 million Americans who have irritable bowel syndrome (IBS), a significant number avoid seeing their families, attending parties and even shopping during the holiday season because of their digestive disorder. Running to the bathroom and unpredictable digestive symptoms often make road trips difficult, socializing embarrassing and enjoying popular holiday meals nearly impossible. For the approximately one in five Americans...

British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec. 2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday season is, for most, anticipated with excitement. But for the estimated 60 million Americans who suffer from Irritable Bowel Syndrome (IBS), the holidays can be fraught with the fear of sudden embarrassing and debilitating gastrointestinal attacks, often triggered by...

As people age, changes in the digestive tract make occasional digestive issues more likely. In fact, nearly 70 million Americans have some sort of digestive issue every year, and as many as 40% of older, boomer-aged adults have one or more symptoms related to digestive concerns. Enzymatic Therapy(R) has launched the answer for baby boomers wondering what happened to their digestive systems - CompleteGest(1) Renew age-optimized enzymes. Most boomers remember when they could eat whatever...

Ironwood Pharmaceuticals has reported positive results from a Phase IIb study assessing linaclotide's safety and efficacy in 420 patients with irritable bowel syndrome with constipation. Analysis of the data indicates that once-daily oral dosing of linaclotide, across a range of doses, significantly reduced abdominal pain and significantly improved constipation symptoms in patients with irritable bowel syndrome with constipation (IBS-C) throughout the 12-week study period. Further, the...

Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA(R)). These trials were conducted between November 2001 and January 2005 and the results were previously reported in the United States. These data demonstrate that lubiprostone provided significant improvements in subjective assessments of symptoms and was well tolerated...

Enzymatic Therapy(R), the manufacturer and distributor of over 200 nutritional supplements and natural medicines, has launched a GREAT-tasting, natural solution for occasional heartburn and digestive upset - DGL ULTRA extra-strength deglycyrrhizinated licorice.(1) For nearly 30 years, Enzymatic Therapy's original DGL (Deglycyrrhizinated Licorice) has been used to support healthy digestive function.(1) Now, Enzymatic Therapy has launched extra-strength, German Chocolate-flavored DGL...

By Lois M. Collins Deseret News Women hate to discuss certain things, even with a trusted physician. So they often wait a long time before mentioning chronic diarrhea, fecal incontinence, urinary urgency, flatulence and other digestive tract woes, according to Dr. Holly Clark, a gastroenterologist at LDS Hospital. Those silent women's health issues -- "silent" because they are often unacknowledged or discussed -- are the topic of Saturday's Deseret News/Intermountain Healthcare Hotline....

Ironwood Pharmaceuticals and Forest Laboratories have reported positive results from a Phase IIb study assessing linaclotide's safety and efficacy in 420 patients with irritable bowel syndrome with constipation. Analysis of the data indicates that once- daily oral dosing of linaclotide, across a range of doses, significantly reduced abdominal pain and significantly improved constipation symptoms in patients with irritable bowel syndrome with constipation (IBS-C) throughout the 12-week study...

SAN DIEGO, Oct. 7 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, today announced findings from its development of PROMETHEUS(R) IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). The findings suggest measurable differences in the expression of particular biomarkers in blood samples between IBS and non-IBS patients. The identification of these biomarkers, combined with a proprietary algorithm, led to the development of...